You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
澤璟製藥(688266.SH)2022年度預虧3.89億至5.21億元、1類新藥多納非尼片納入國家醫保目錄
格隆匯 01-28 16:44

格隆匯1月28日丨澤璟製藥(688266.SH)公佈,公司預計2022年年度實現營業收入28052.29萬元到32930.95萬元,比上年同期增加9016.23萬元到13894.89萬元,同比增加47.36%到72.99%。

公司預計2022年度歸屬於上市公司股東的淨利潤為-52088.26萬元至-38923.40萬元,比上年同期虧損增加6988.34萬元到虧損減少6176.52萬元,同比增虧15.50%到減虧13.70%。

公司預計2022年度扣除非經常性損益後歸屬於上市公司股東的淨利潤為-56189.75萬元至-42279.16萬元,比上年同期虧損增加6411.33萬元到虧損減少7499.25萬元,同比增虧12.88%到減虧15.07%。

公司預計2022年度研發費用約46781.44萬元到52753.54萬元,比上年同期減少4157.98萬元到增長1814.12萬元,同比減少8.16%到增長3.56%。

報吿期公司1類新藥多納非尼片納入國家醫保目錄,商業化推廣穩步推進,醫保準入醫院和雙通道藥房持續增加,銷售收入實現較快增長。

隨着新藥研發管線持續推進,多個創新藥物處於關鍵試驗研究階段,研發投入保持較高水平。同時,公司商業化能力尚處於前期建設階段,仍需持續投入較多的市場宣傳和學術推廣活動開支。由於多納非尼片上市時間較短,重組人凝血酶、鹽酸傑克替尼片處於新藥上市前註冊和審評流程中,本期實現的藥品銷售收入暫時無法覆蓋各項成本及費用,因此,公司2022年度淨利潤仍然為負,扣除非經常性損益前後均虧損。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account